Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)
NCT ID: NCT03247439
Last Updated: 2020-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
74 participants
INTERVENTIONAL
2017-12-22
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 74 subjects will be enrolled into the pivotal study.
Follow up visits will occur at the following time points after the surgical procedure: 2 week, 6 week, 3 month, 6 month, 1 year, 2 year, 3 year, 4 year and 5 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cartiva
Synthetic Cartilage Implant
Cartiva
Synthetic Cartilage Implant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cartiva
Synthetic Cartilage Implant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory to conservative non-operative standard of care treatment for first CMC OA lasting for at least 6 months that requires surgical intervention
* Eaton classification stage II or III OA of the first CMC joint based on X-rays taken within 6 months of the Operative date and evidence of first CMC joint OA based on subjective review of associated clinical symptoms
* Preoperative VAS Pain score of ≥ 40 in the treated hand
* Preoperative 11 question QuickDASH score of ≥ 20
* Presence of good bone stock - i.e., no need for bone graft
* Capable of completing self-administered questionnaires
* Be willing and able to return for all study-related follow up procedures
* Have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the IRB/REB/Ethics Committee
Exclusion Criteria
* Active infection at the site of surgery
* Previous CMC implant, trapeziectomy, or LRTI to the affected joint to be treated
* Inflammatory arthropathy and/or diagnosis of grout
* History of or current diagnosis of rheumatoid arthritis
* Any significant bone loss, avascular necrosis, or cyst \> 8mm of the supporting bone structure
* Eaton classification stage IV advanced OA of the first CMC joint based on X-rays taken within 6 months of the Operative date
* Physical conditions that would tend to eliminate adequate implant support (e.g., inadequate cortical bone stock of at least 2mm circumferentially insufficient quality or quantity of bone resulting from cancer, congenital dislocation, or osteoporosis), systemic and metabolic disorders leading to progressive deterioration of bone (e.g., cortisone therapies or immunosuppressive therapies), and/or tumors and/or cysts of the supporting bone structures
* OA of the scaphotrapeziotrapezoidal (STT) joint based on radiographic assessment in the hand to be treated
* Any disease, including uncontrolled diabetes mellitus, which is clinically known to impact wound healing ability
* Known or suspected allergic reaction to polyvinyl alcohol
* Patient is on chronic anticoagulation due to a bleeding disorder or has taken anticoagulants within 3 days prior to surgery
* Diagnosed with cancer in the last two years and received treatment with chemotherapy or received radiation to the upper extremity to be treated with Cartiva
* Any medical condition that makes the subject unsuitable for inclusion in the study, including, but not limited to, patients with a diagnosis of concomitant injury that may interfere with healing; patients with clinically significant renal, hepatic, cardiac, endocrine, hematologic, autoimmune or any systemic disease or systemic infection which may make interpretation of the results difficult; patients who have undergone systemic administration within 30 days prior to implantation of any type of corticosteroid in the thumb, antineoplastic, immunostimulating or immunosuppressive agents
* Have participated in any other investigational or invasive clinical trial within the last three months, and will not participate in any other investigational or invasive clinical trial during this study
* Co-morbidity that reduces life expectancy to less than 12 months
* If female, be pregnant, planning to become pregnant during the course of the study, breast-feeding, or if childbearing age, is not using contraception
* Current or recent history of substance abuse (e.g., recreational drugs, narcotics, or alcohol) requiring intervention
* Is a prisoner or ward of the state
* Is unable to meet the treatment and follow up protocol requirements
* Is being compensated under workers' compensation or are currently involved in litigation that is related to the musculoskeletal system
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cartiva, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Wolfe, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital for Special Surgery, New York
Christopher Bainbridge, MB ChB, FRCSEd, CCST
Role: PRINCIPAL_INVESTIGATOR
Royal Derby Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Diego
San Diego, California, United States
Georgia Hand, Shoulder & Elbow
Atlanta, Georgia, United States
Indiana Hand to Shoulder Center
Indianapolis, Indiana, United States
Hospital for Specialty Surgery
New York, New York, United States
University of Rochester
Rochester, New York, United States
Royal Derby Hospital
Derby, Derbyshire, United Kingdom
Dorset County Hospital
Dorchester, Dorset, United Kingdom
Queen Alexandra Hospital
Portsmouth, Hampshire, United Kingdom
South Tees Hospitals
Middlesbrough, North Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTC-0290
Identifier Type: -
Identifier Source: org_study_id